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Introduction
Schizophrenia and schizoaffective disorder are associated with a 
mortality risk 2–2.5 times greater than that of the general popula-
tion (Chang et al., 2010) and increased physical morbidity, which 
is highlighted by a 10–20-year reduction in patient life expec-
tancy (Chang et al., 2011).
Antipsychotic medications are frequently used in the treat-
ment of schizophrenia and schizoaffective disorder; however, 
despite their effectiveness in clinical practice, they have been 
associated with significant mortality and physical morbidity (Ray 
et al., 2009; Roden, 2004; Stahl et al., 2009). Mortality risk varies 
between antipsychotics (Crump et al., 2013), and there is emerg-
ing evidence that the choice of antipsychotic treatment may 
impact on a patient’s risk of premature mortality (Hayes et al., 
2014). Clozapine, a second-generation antipsychotic, is effective 
in the treatment of treatment-resistant schizophrenia and schiz-
oaffective disorder (Tiihonen et al., 2017; Wimberley et al., 
2017). Current treatment guidelines restrict clozapine use to a 
third-line treatment (NICE, 2015; Remington et al., 2013) due to 
severe and sometimes fatal adverse effects, including agranulo-
cytosis (Kumra et al., 2008; Nielsen et al., 2012). Despite these 
safety concerns, studies have reported that clozapine is associ-
ated with a decreased mortality risk, compared with other antip-
sychotics (Hayes et al., 2014; Wimberley et al., 2017). There are 
also corresponding improvements in symptoms and functioning 
(De Oliveira-Souza et al., 1999; Wahlbeck et al., 2009), which 
are the ideal measures of assessing the efficacy of clozapine, in 
accordance to usual clinical practice.
The heterogeneous nature of schizophrenia and schizoaffec-
tive disorder and their clinical presentations make it difficult to 
directly assess the effects of clozapine on symptomology in real-
world settings. Given these difficulties, patterns of readmission 
into mental health services has been demonstrated to be a reliable 
marker for symptoms and functioning (Ahn et al., 2005; Conley 
et al., 1999; Pollack et al., 1998; Schooler et al., 1997).
Unfortunately, there is a limited pool of research focusing on 
the association between clozapine and risk of readmission. The 
majority of studies to date have found that clozapine is associated 
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with a decreased risk of readmission (Ahn et al., 2005; Castro and 
Elkis, 2007; Essock et al., 1996; Gee et al., 2016; Pridan et al., 
2015; Tiihonen et al., 2017; Valevski et al., 2012), although one 
study reported no association (Lin et al., 2006). The association 
with decreased risk of readmission has also been supported in a 
recent meta-analysis of an extensive list of studies (Land et al., 
2017). However, these studies suffer from a number of limitations 
including neglecting to control for important confounding varia-
bles (Ahn et al., 2005; Castro and Elkis, 2007; Essock et al., 1996; 
Gee et al., 2016; Lin et al., 2006; Pridan et al., 2015; Valevski et al., 
2012). Furthermore, confounding-by-indication is an important 
issue which has not been addressed adequately in a number of 
studies (Ahn et al., 2005; Castro and Elkis, 2007; Essock et al., 
1996; Lin et al., 2006; Pridan et al., 2015). Another limitation of 
current research is that no studies to date have specifically investi-
gated the effect of newly prescribed clozapine at discharge on the 
risk of readmission. This is relevant to clinical decision-making 
where clinicians have to decide whether to change or maintain 
medication regimens. Knowing if clozapine would reduce risk of 
readmission at that point in time may aid clinical decision making 
and lessen delays in starting patients on clozapine (Howes et al., 
2012). Furthermore, most studies have only investigated schizo-
phrenia (Ahn et al., 2005; Castro and Elkis, 2007; Lin et al., 2006; 
Pridan et al., 2015; Valevski et al., 2012), which does not reflect the 
current clinical environment, where clozapine is used in the treat-
ment of both treatment-resistant schizophrenia and schizoaffective 
disorder. Also, the age ranges included in current literature are 
either limited (Ahn et al., 2005; Pridan et al., 2015) or not men-
tioned at all (Castro and Elkis, 2007; Essock et al., 1996; Lin et al., 
2006). Thus, we attempted to address these limitations in this cur-
rent study by using a large cohort with rich contextual information, 
therefore permitting to investigate and control an array of possible 
confounders.
Aims of the study
The aim of this study was to investigate the effect of newly pre-
scribed clozapine to people with schizophrenia and schizoaffec-
tive disorder on the risk of readmission into secondary mental 
health services, compared with those on other antipsychotics. We 
hypothesised that newly prescribed clozapine reduces the risk of 
readmission into secondary mental health services in patients 
with schizophrenia and schizoaffective disorder.
Material and methods
Setting
This study used patient data from an extensive, anonymised elec-
tronic mental health records database, the South London and 
Maudsley NHS Foundation Trust (SLaM) Case Register. As 
mental health services in the UK are provided according to geo-
graphic catchment areas under the NHS, SLaM provides mental 
health care for approximately 1.36 m residents from four London 
boroughs (Lambeth, Southwark, Lewisham and Croydon). 
Clinical records have been maintained electronically by SLaM 
services since 2006. At the time this study was conducted 
researchers were able to search for information on the records on 
over 250,000 patients using the Clinical Record Interactive 
Search (CRIS) system, an application drawing and anonymising 
clinical record data for use in research (Perera et al., 2016).
Ethics statement
The Oxfordshire Research Ethics Committee C (08/H0606/71) 
approved the CRIS system as an anonymised data resource for 
secondary analysis, with governance provided for related pro-
jects by a patient-led oversight committee.
Inclusion criteria
The patient cohort constituted all individuals who had been diag-
nosed with schizophrenia or schizoaffective disorder (World 
Health Organisation (WHO) International Classification of 
Diseases 10 (ICD-10) codes: F20, F25) in SLaM during the 
observation period (between 1 January 2007–31 December 
2014), and who were aged between 15–95 years at index dis-
charge (defined below). Within the observation period, these 
patients had at least one inpatient episode where they were dis-
charged on an antipsychotic (either clozapine or another drug). 
The first discharge within the observation period where patients 
were prescribed an antipsychotic constituted the definition of 
index discharge. However, in patients prescribed clozapine, 
index discharge was defined as the first discharge within the 
observation period where they were discharged on clozapine, 
regardless of whether they had been discharged on another antip-
sychotic beforehand. Patients who were discharged on more than 
one antipsychotic at their index discharge were excluded from 
the cohort. Patients who were prescribed clozapine prior to their 
index discharge were also excluded since this study investigated 
the impact of being newly prescribed clozapine on risk of 
readmission.
Data extraction
Data were available for extraction from structured fields in CRIS. 
However, additional information was also provided in free-text 
fields. Extracting information from free-text fields was carried 
out using applications built using Generalised Architecture for 
Text Engineering (GATE) (Cunningham et al., 2013). GATE is a 
commonly used program featuring a variety of tools to facilitate 
natural language processing tasks, including information extrac-
tion from clinical notes. These applications take into account the 
linguistic context when extracting data from the free text, ena-
bling automated extraction and coding of data on a large scale. 
They are therefore more sophisticated and validated than basic 
key word searches. The technique of natural language processing 
makes it possible to differentiate between instances where the 
word 'clozapine' is used in the context of a current prescription, 
or other less relevant contexts (Hayes et al., 2014).
Main outcome measure
Readmission to SLaM services was defined as inpatient admis-
sion to SLaM services following index discharge which was 
within the observation period. Information about readmission 
was extracted from structured fields.
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Care was taken to ensure that mortality was not mistaken as a 
lack of readmission. Routine nationwide mortality tracing linked 
to the electronic health record was used to determine mortality of 
all causes (Chang et al., 2010). All death certifications in the UK 
are linked to an NHS number (a unique UK NHS medical record 
identifier), which are all checked monthly against the national 
mortality database and kept up-to-date.
Main exposure
The main exposure of interest was the antipsychotic regime 
established at point of discharge and sustained during transition 
to community settings. This was determined based on an antipsy-
chotic prescription being given during the inpatient episode and 
the same drug being prescribed again at some point within the six 
weeks after they were discharged. Six weeks was our chosen 
interval to ensure all documents regarding discharge were cap-
tured, as there may sometimes be a delay between discharge and 
the clinician entering notes online. Information regarding medi-
cation regimens was extracted from pharmacy data, structured 
fields and free-text fields (with the use of natural language pro-
cessing applications) in the SLaM Case Register (Hayes et al., 
2014). Where patients had not been prescribed clozapine at any 
stage during the observation period, the first inpatient episode 
where the patient was prescribed an antipsychotic was selected. 
If patients had been prescribed clozapine, then the first discharge 
on clozapine was used, even if the patient had been discharged on 
another antipsychotic at an earlier date. The follow-up period 
commenced at the first discharge date where patients were pre-
scribed clozapine or a conventional antipsychotic during the 
observation period, through to their first readmission, date of 
death, or the end of the observation period (31 December 2014), 
whichever occurred first.
Covariates
We examined a number of demographic, socio-economic and 
clinical confounders. For this study, we derived a number of 
potential confounding variables from the Health of the Nation 
Outcome Scale (HoNOS) instrument. HoNOS was used because 
it is commonly used by clinicians after routine assessments in 
UK mental health services as a standard measure of patient well-
being and has been well validated (Hunter et al., 2009; Orrell 
et al., 1999; Pirkis et al., 2005; Wing et al., 1998).
Demographic and socioeconomic factors that we examined 
were: age, gender, ethnicity, marital status and deprivation. Age, 
gender, ethnicity and marital status were derived from structured 
fields in CRIS. Age was calculated on the discharge date, and 
was converted into a categorical variable of three age categories. 
Ethnicity was collapsed into the following subcategories: white, 
other White, South Asian, East Asian, Caribbean, other Black 
and mixed or unknown. Marital status included whether patients 
were married or cohabiting. Socioeconomic status was measured 
using an area-level index of multiple deprivation based on the 
patients’ residence. This index includes several area-level 
domains of deprivation, provided by the 2001 national UK cen-
sus (barriers to services and housing, crime, education, employ-
ment, income, health, living). Each domain was weighted 
according to its importance. The address of the patient used was 
the one recorded closest to the time they entered the study, with a 
separate category assigned to homeless patients.
Further clinical confounders included in the analysis were: 
diagnosis, HoNOS subscales of agitated behaviour, hallucinations 
and delusions, depressed mood and prior community treatment 
orders (CTOs) or depot medication. Multiple diagnoses may be 
given over the time that patients are in contact with SLaM ser-
vices. We selected the diagnosis assigned closest to index dis-
charge, and was categorised in accordance to ICD-10 diagnoses 
(F20, F25) and were extracted from free text using GATE, 
described above, and structured fields. The HoNOS subscales of 
agitated behaviour, hallucinations and delusions, and depressed 
mood, assessed the severity of symptoms. The HoNOS scores 
were extracted from structured fields and collapsed into three cat-
egories of severity from the original five due to small cell size. 
The first of the three categories contained the original first cate-
gory: no problem. The second of the three categories contained 
the original second category: minor problem requiring no action. 
The third of the three categories contained the original third, 
fourth and fifth categories respectively defined as: mild problem 
but definitely present, moderately severe problem, and severe to 
very severe problem. These scores were based on the HoNOS 
which had been administered closest to but prior to index dis-
charge. However, if prior scores were not available, data from the 
HoNOS was administered on the closest date after the index 
discharge.
Additional mental and physical health problems comprised 
HoNOS subscales of self-injury, drinking or drug taking, cogni-
tive problems, other mental problems (phobic, anxiety, obses-
sive-compulsive, mental strain/tension, dissociative, somatoform, 
eating, sleep, sexual, other) and physical illness. Functional sta-
tus comprised HoNOS subscales of daily living problems, living 
condition problems, occupational problems and relationship 
problems. As explained above, the scores were extracted from 
structured fields and collapsed into three categories of severity, 
and were assigned closest to index discharge, but preferentially 
beforehand.
Substance use disorders comprised diagnoses of alcohol use 
disorder (ICD-10: F10) or opioid use disorder (ICD-10: F11) any 
time prior to index discharge. This information was extracted 
from free text using GATE described above, and structured fields.
CTOs, legal orders under which a patient must accept treat-
ment, and long-acting depot injections are indicated for patients 
non-adherent to their medication regimens, and can be adminis-
tered in England and Wales under the Mental Health Act 2007. 
As such, a variable for whether patients had ever had CTOs or 
depots prior to index discharge was used in a sensitivity analysis, 
as a marker of potential non-adherence, based on the view that 
those with past non-adherence may be more likely to be non-
adherent during follow-up.
Statistical analysis
Statistical analysis was carried out using Stata, version 13. 
Demographic and other details pertaining to the confounding 
variables described above were first defined for the study cohort 
as a whole. Patients who were prescribed clozapine during the 
follow-up period were then compared to those not prescribed clo-
zapine with respect to these potential confounding variables, 
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using Pearson’s chi-squared test. Cox regression procedures were 
used, after checking the proportional hazard assumption, to 
model associations between clozapine and risk of readmission. 
An alternative analysis comparing risk of readmission between 
clozapine and olanzapine was also carried out. Several Cox anal-
yses were modelled, including a crude analysis, and multivaria-
ble analyses controlling for each of the aforementioned categories 
of covariates, with the final model adjusting for all those exam-
ined. Propensity scores were used to address the issue of con-
founding-by-indication. These scores indicated the probability of 
being prescribed clozapine within the observation period, and 
included factors included in the fully adjusted model. The pro-
pensity scores were used in two ways. Firstly, a fully adjusted 
Cox analysis was carried out with the propensity score included 
as a covariate replacing the other potential confounder. Secondly, 
another fully adjusted Cox model included only those who had at 
a near-equal probability of being prescribed clozapine or not pre-
scribed clozapine based on their propensity scores, in order to 
restrict the analysis to patients at a similar stage in their illness.
Next, the following fully adjusted sensitivity analyses were 
carried out: (a) excluding patients treated with prior depot medi-
cation or CTOs (as noncompliance and not taking medication 
could mean that these patients are being incorrectly assigned to 
the exposure group); (b) restricting the sample to patients diag-
nosed with ICD-10 F20 schizophrenia (to ensure the association 
persisted in the schizophrenia group enabling a comparison of 
these results with other studies which focus on schizophrenia); 
(c) excluding patients treated in one of the four London boroughs 
(Lewisham) as pharmacy data regarding clozapine exposure was 
incomplete in that borough; (d) comparing patients prescribed 
clozapine with those prescribed olanzapine at discharge; (e) 
excluding patients prescribed fewer than two antipsychotics prior 
to index discharge; (f) restricting our cohort to those who were at 
risk of being both treated or untreated with clozapine (based on 
propensity scores); (g) excluding patients outside our geographic 
catchment.
A Kaplan–Meier curve was produced to visualise the fully 
adjusted Cox regression.
Results
Over the seven-year observation period between 1 January 2007–
31 December 2014, 4705 patients with a diagnosis of schizophre-
nia or schizoaffective disorder and sufficient data for initial 
inclusion were identified. After applying the inclusion criteria 
and data cleaning the final sample for analysis included 3651 
patients, as explained by Figure 1.
The mean follow-up period was 817 days, with a standard 
deviation (SD) of 782 days. The total follow-up time was 8163 
person-years. The GATE application that was used to extract data 
on antipsychotic prescriptions from electronic patient records 
was validated against manual review of 30 records, with a preci-
sion (positive predictive value) of 93%.
Table 1 provides data on patient characteristics for the sample 
used in this analysis. The ages of patients ranged from 15–95 
years, with a mean age of 40.1 years and a standard deviation of 
14.8. The majority of patients were male (58.6%), and reflected 
the ethnic diversity of South London, with nearly two-thirds of 
patients with a black, Asian or mixed ethnic background. Two 
hundred and two patients (5.5%) were prescribed clozapine and 
3449 (94.5%) were prescribed another antipsychotic drug. The 
majority of patients were diagnosed with schizophrenia (89.3%) 
and experienced problems with hallucinations and delusions 
(71%).
Table 2 shows comparisons between patients with or without 
exposure to clozapine. Those prescribed clozapine were more 
likely to be male, single and to have received schizophrenia as a 
primary diagnosis, to a statistically significant level (p<0.05). 
Patients prescribed clozapine were more likely to function more 
poorly with regards to problems with daily living and occupation, 
and have more severe psychopathology, including problems with 
agitated behaviour, hallucinations and delusions, depressed 
mood, drinking or drug taking, cognitive problems and other 
mental problems. They were also more likely to have been on 
prior depot medication or CTOs. A smaller percentage of patients 
newly prescribed clozapine were readmitted into mental health 
services (44.1% (n=89) compared with of non-clozapine users 
54.2% (n=1869) (p<0.05)). Figure 2 displays Kaplan–Meier 
curves for patients prescribed clozapine and not prescribed 
clozapine.
Table 3 displays Cox regression models investigating the 
association between clozapine exposure and readmission. 
Clozapine was associated with a reduced risk of readmission in 
the crude analysis, hazard ratio (HR) 0.73 (95% confidence inter-
val (CI): 0.59–0.91; p=0.004), and fully adjusted models, 
adjusted hazard ratio (aHR) 0.79 (95% CI: 0.64–0.99; p=0.043). 
This association also persisted when carrying out fully adjusted 
sensitivity analyses: excluding noncompliance (aHR 0.73 (95% 
CI: 0.57–0.94); p=0.013), restricting to schizophrenia (aHR 0.76 
(95% CI: 0.60–0.96); p=0.024), excluding patients from 
Lewisham (aHR 0.74 (0.56–0.96); p=0.025). This association 
also persisted in a fully adjusted model based on propensity 
scores, which included only those who had at a near-equal prob-
ability of being prescribed clozapine or not prescribed clozapine, 
aHR 0.80 (95% CI: 0.64–1.00; p=0.047). Clozapine also reduced 
risk of readmission more than olanzapine in a fully adjusted 
model, aHR 0.76 (95% CI: 0.60–0.96; p=0.021). A further sensi-
tivity analysis was carried out to fully exclude all patients outside 
the designated geographic catchment, as external patients are 
more likely to have been those treated by the National Psychosis 
Unit, Psychiatric Intensive Care Units, and forensic units, which 
tend to admit more patients from outside the boroughs due to 
their clinical complexity. These patients are therefore less likely 
to have readmission data. In this sensitivity analysis, this associa-
tion was not present, HR 0.87 (95% CI: 0.69–1.09; p=0.228). A 
final sensitivity analysis was also carried out to exclude all 
patients who had been prescribed fewer than two antipsychotics, 
where this association was also no longer significant, HR 0.79 
(95% CI: 0.62–1.00; p=0.054).
Discussion
This study tested the hypothesis that newly prescribed clozapine 
use, in the treatment of schizophrenia and schizoaffective disor-
der, is associated with a decreased risk of readmission compared 
with treatment with conventional antipsychotics. We found evi-
dence that clozapine was associated with a moderately lower risk 
of readmission, supporting the hypothesis. Although patients 
who were newly prescribed clozapine were more ill at baseline, 
had poorer functional status and more severe psychopathology, 
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they had a lower risk of readmission as compared with patients 
not prescribed clozapine. This association remained after adjust-
ing for a large variety of confounding factors including: demo-
graphic, socioeconomic and clinical factors. This association 
persisted following several sensitivity analyses and the use of 
propensity scores to address confounding-by-indication. 
However, when carrying out the sensitivity analysis excluding all 
patients outside the designated geographic catchment, and the 
sensitivity analysis excluding patients who had been prescribed 
fewer than two antipsychotics prior to index discharge, the direc-
tion of the association remained and the effect estimate was simi-
lar, but the association was no longer significant. This is most 
likely due to the substantial reduction in sample size and there-
fore loss of power for these analyses.
These findings are consistent with several other studies, 
which have also found an association between clozapine and a 
decreased risk of readmission. For example, a retrospective anal-
ysis of 117 schizophrenia patients prescribed clozapine in South 
Korea found that their readmission rates were lower after initia-
tion on clozapine compared with beforehand, and that this asso-
ciation was still present five years after initiation on clozapine 
(p<0.01) (Ahn et al., 2005). This study was restricted to patients 
with schizophrenia. When we restricted our sample to only pat-
ents with schizophrenia we still saw a significant protective 
effect of clozapine. These findings are also consistent with more 
recent studies. A recent definitive meta-analysis found that clo-
zapine was associated with a reduction in the proportion of 
admissions into hospital compared with other antipsychotics 
including olanzapine (risk ratio = 0.74; 95% CI: 0.69–0.80; 
p<0.001) (Land et al., 2017). A recent cohort study using nation-
wide databases included traditional Cox proportional hazards 
models and within-individual Cox proportional hazards models. 
Clozapine was also associated with a reduced risk of readmission 
(HR 0.53; 95% CI: 0.48–0.58) (Tiihonen et al., 2017). However, 
existing research has failed to adjust for important time-depend-
ent potential confounders such as changes in symptoms. As pre-
viously discussed, this highlights ongoing limitations in current 
research with regards to limited controlling for confounding 
variables.
This study had several strengths. Firstly, we were able to 
capture and adjust for a number of important clinical, sociode-
mographic and socio-economic variables, which limited the 
Figure 1. Flow chart outlining process undertaken to attain final sample size.
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Table 1. Sample characteristics patient cohort, including South London 
and Maudsley NHS Foundation Trust (SLaM) patients with schizophrenia 
and schizoaffective disorder, discharged on antipsychotic monotherapy 
between 1 January 2007–31 December 2014, and met the inclusion 
criteria (n=3651).
Risk factors n Individuals
(Percentage within 
category)
Total 3651 (100%)
Taking clozapine during follow-up period  
No 3449 (94.5%)
Yes 202 (5.5%)
Demographic and socioeconomic factors  
Age (mean 40.1, SD 14.8, range 15–95 years)  
15–34 years 1494 (40.9%)
35–54 years 1620 (44.4%)
55 years and over 537 (14.7%)
Gender  
Female 1512 (41.4%)
Male 2139 (58.6%)
Ethnicity  
White 978 (26.8%)
Other White 277 (7.6%)
South Asian 71 (1.9%)
East Asian 139 (3.8%)
Caribbean 484 (13.3%)
Other Black 1413 (38.7%)
Mixed unknown 289 (7.9%)
Married or cohabiting  
No 3278 (89.8%)
Yes 373 (10.2%)
Deprivation level in area of residence  
(tertiles)
3585
Low levels of deprivation 1155 (32.2%)
Medium levels of deprivation 1154 (32.2%)
High levels of deprivation 1156 (32.3%)
Homeless 120 (3.4%)
Diagnosis and severity of symptoms  
Diagnosis  
Schizophrenia (ICD10 code- F20) 3259 (89.3%)
Schizoaffective disorder (ICD10 code-F25) 392 (10.7%)
Agitated behaviour 3561
Not a problem 2083 (58.5%)
Minor problems only 776 (21.8%)
Significant problem 702 (19.7%)
Hallucinations and delusions 3552
Not a problem 1029 (29.0%)
Minor problems only 814 (22.9%)
Significant problem 1709 (48.1%)
Depressed mood 3555
Not a problem 1809 (50.9%)
Minor problems only 1043 (29.3%)
Significant problem 703 (19.8%)
Ever had a community treatment order  
No 3581 (98.1%)
Yes 70 (1.9%)
Risk factors n Individuals
(Percentage within 
category)
Ever been on depot medication  
No 3266 (89.5%)
Yes 385 (10.6%)
Additional mental and physical health 
problems
 
Self-injury 3559
Not a problem 3166 (89.0%)
Minor problems only 189 (5.3%)
Significant problem 204 (5.7%)
Problem-drinking or drug taking 3528
Not a problem 2566 (72.7%)
Minor problems only 336 (9.5%)
Significant problem 626 (17.7%)
Cognitive problems 3554
Not a problem 2217 (62.4%)
Minor problems only 761 (21.4%)
Significant problem 576 (16.2%)
Other mental problems 3551
Not a problem 1335 (37.6%)
Minor problems only 910 (25.6%)
Significant problem 1306 (36.8%)
Physical illness 3550
Not a problem 2470 (69.6%)
Minor problems only 512 (14.4%)
Significant problem 568 (16.0%)
Functional status  
Daily living problems 3527
Not a problem 1786 (50.6%)
Minor problems only 891 (25.3%)
Significant problem 850 (24.1%)
Living conditions problems 3457
Not a problem 1885 (54.5%)
Minor problems only 733 (21.2%)
Significant problem 839 (24.3%)
Occupational problems 3449
Not a problem 1349 (39.1%)
Minor problems only 1008 (29.2%)
Significant problem 1092 (31.7%)
Relationship problems 3523
Not a problem 1390 (39.5%)
Minor problems only 1020 (29.0%)
Significant problem 1113 (31.6%)
Substance use disorders  
Ever diagnosed with alcohol use  
disorder
 
No 3355 (91.9%)
Yes 296 (8.1%)
Ever diagnosed with opioid use  
disorder
 
No 3591 (98.4%)
Yes 60 (1.6%)
ICD-10: International Classification of Diseases 10; SD: standard deviation.
Table 1. (Continued)
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Table 2. Sample characteristics comparing those prescribed clozapine 
with those not prescribed clozapine, including South London and 
Maudsley NHS Foundation Trust (SLaM) patients with schizophrenia 
and schizoaffective disorder, discharged on antipsychotic monotherapy 
between 1 January 2007–31 December 2014, and met the inclusion 
criteria (n=3651).
Risk factors Not prescribed 
clozapine
Prescribed 
clozapine
n (%) n (%)
Total 3449 202
Readmissiona 1869 (54.2%) 89 (44.1%)
Demographic and socioeconomic 
factors
 
Age  
15–34 years 1401 (40.6%) 93 (46.0%)
35–54 years 1533 (44.5%) 87 (43.1%)
55 years and over 515 (14.9%) 22 (10.9%)
Gendera  
Female 1446 (41.9%) 66 (32.7%)
Male 2003 (58.1%) 136 (67.3%)
Ethnicitya  
White 906 (26.3%) 72 (35.6%)
Other White 263 (7.6%) 14 (6.9%)
South Asian 63 (1.8%) 8 (4.0%)
East Asian 133 (3.9%) 6 (3.0%)
Caribbean 472 (13.7%) 12 (5.9%)
Other Black 1338 (38.8%) 75 (37.1%)
Mixed or unknown 274 (7.9%) 15 (7.4%)
Married or cohabiting  
No 3089 (89.6%) 189 (93.6%)
Yes 360 (10.4%) 13 (6.4%)
Deprivation level in area of resi-
dence (tertiles)
 
Low levels of deprivation 1078 (31.8%) 77 (38.9%)
Medium levels of deprivation 1097 (32.4%) 57 (28.8%)
High levels of deprivation 1098 (32.4%) 58 (29.3%)
Homeless 114 (3.4%) 6 (3.0%)
Diagnosis and severity of symptoms  
Diagnosis  
Schizophrenia (ICD10 code- F20)a 3075 (89.2%) 184 (91.1%)
Schizoaffective disorder (ICD10 
code- F25)
374 (10.8%) 18 (8.9%)
Agitated behavioura  
Not a problem 1939 (57.7%) 144 (72.4%)
Minor problems only 749 (22.3%) 27 (13.6%)
Significant problem 674 (20.1%) 28 (14.1%)
Hallucinations and delusions  
Not a problem 980 (29.2%) 49 (24.8%)
Minor problems only 775 (23.1%) 39 (19.7%)
Significant problema 1599 (47.7%) 110 (55.6%)
Depressed mood  
Not a problem 1702 (50.8%) 107 (53.8%)
Minor problems only 979 (29.2%) 64 (32.2%)
Significant problem 675 (20.1%) 28 (14.1%)
Ever had a community treatment 
ordera
 
No 3390 (98.3%) 191 (94.5%)
Yes 59 (1.7%) 11 (5.5%)
Risk factors Not prescribed 
clozapine
Prescribed 
clozapine
n (%) n (%)
Ever been on depot medicationa  
No 3097 (89.8%) 169 (83.7%)
Yes 352 (10.2%) 33 (16.3%)
Additional mental and physical 
health problems
 
Self-injury  
Not a problem 2987 (88.9%) 179 (90.4%)
Minor problems only 176 (5.2%) 13 (6.6%)
Significant problem 198 (5.9%) 6 (3.0%)
Problem-drinking or drug takinga  
Not a problem 2413 (72.4%) 153 (77.7%)
Minor problems only 314 (9.4%) 22 (11.2%)
Significant problem 604 (18.1%) 22 (11.2%)
Cognitive problemsa  
Not a problem 2114 (63.0%) 103 (52.0%)
Minor problems only 708 (21.1%) 53 (26.8%)
Significant problem 534 (15.9%) 42 (21.2%)
Other mental problems  
Not a problem 1265 (37.7%) 70 (35.4%)
Minor problems onlya 840 (25.1%) 70 (35.4%)
Significant problem 1248 (37.2%) 58 (29.3%)
Physical illness  
Not a problem 2343 (69.9%) 127 (64.1%)
Minor problems only 474 (14.1%) 38 (19.2%)
Significant problem 535 (16.0%) 33 (16.7%)
Functional status  
Daily living problemsa  
Not a problem 1709 (51.4%) 77 (38.7%)
Minor problems only 831 (25.0%) 60 (30.2%)
Significant problem 788 (23.7%) 62 (31.2%)
Living conditions problems  
Not a problem 1767 (54.2%) 118 (60.8%)
Minor problems only 697 (21.4%) 36 (18.6%)
Significant problem 799 (24.5%) 40 (21.0%)
Occupational problems  
Not a problem 1285 (39.5%) 64 (33.3%)
Minor problems only 943 (29.0%) 65 (33.9%)
Significant problem 1029 (31.6%) 65 (32.8%)
Relationship problems  
Not a problem 1318 (39.6%) 72 (36.5%)
Minor problems only 956 (28.7%) 64 (32.5%)
Significant problem 1052 (31.6%) 61 (31.0%)
Substance use disorders  
Ever diagnosed with alcohol use 
disorder
 
No 3167 (91.8%) 188 (93.1%)
Yes 282 (8.2%) 14 (6.9%)
Ever diagnosed with opioid use 
disorder
 
No 3391 (98.3%) 200 (99.0%)
Yes 58 (1.7%) 2 (1.0%)
ICD-10: International Classification of Diseases 10.
aValue of p<0.05 for comparison between those who were and were not pre-
scribed clozapine.
Table 2. (Continued)
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possibility of residual confounding. Confounding-by-
indication was also addressed using propensity scores and a 
sensitivity analysis excluding patients who had been prescribed 
fewer than two antipsychotics prior to index discharge. 
Although this study did not directly address the possibility that 
the promising results associated with clozapine may be due to 
more frequent specialist follow-up in patients taking clozapine 
compared with those taking other antipsychotics, as is common 
clinical practice in the UK, this has been addressed in a previ-
ous study, which found that this is not the case (Hayes et al., 
2014). The risk of readmission for those newly prescribed clo-
zapine was also compared with olanzapine, showing that it 
offers more protective effects than a commonly used antipsy-
chotic. This also allowed comparisons with other mental health 
services where the distribution of antipsychotics in the non-
clozapine comparison group may be different than SLaM. 
Also, if the non-clozapine antipsychotics prescribed within 
SLaM were comparatively ineffective to those prescribed 
within other mental health services, this may have caused an 
overestimation of the protective effect of clozapine. Thus, 
comparing clozapine with olanzapine addressed this. Moreover, 
as the patient sample constituted all patients with schizophre-
nia and schizoaffective disorder in contact with SLaM mental 
health secondary care which serves a defined geographic 
catchment over a seven-year period, it is likely that these data 
are representative of patients with schizophrenia and schizoaf-
fective disorder living in suburban and urban areas. This is 
because SLaM is a near-monopoly provider of mental health 
services within its geographic catchment.
This study also had a number of limitations. Firstly, as the 
focus of this investigation was the effect of being discharged on 
newly prescribed clozapine on hospital readmission, it did not 
elucidate the long-term effect of being prescribed clozapine. This 
study limited the cohort to those newly prescribed clozapine in 
order to make clozapine and non-clozapine groups more compa-
rable. A further limitation is that as we measured the first read-
mission after discharge and not subsequent discharges, changes 
in clinical course were not measured, so the longevity and pat-
terns of the protective effects of clozapine on readmission are 
uncertain. Moreover, since only patients on monotherapy were 
included in this investigation, these results may not be applicable 
to patients on polypharmacy. In addition, residual confounding 
may still be present due to factors which were not adjusted for in 
this investigation. This includes factors not mentioned by clini-
cians, as extracted information about patients relied on clinical 
records, in addition to lifestyle factors, such as the possibility that 
patients on clozapine may be exposed to less stress following 
discharge if, for example, they are not expected to work and con-
tribute socially. In particular, confounding-by-indication is an 
important issue in observational studies investing the impact of 
medications. For example, since clozapine is a third-line antipsy-
chotic, patients who are newly prescribed clozapine are more 
likely to be at a later stage in the course of their treatment and 
illness than those who have been newly prescribed another antip-
sychotic. Although propensity scores were used to address this as 
well as a sensitivity analysis excluding patients who had been 
prescribed fewer than two antipsychotics prior to index dis-
charge, confounding-by-indication cannot be completely ruled 
out and there is still potential for bias. However, as previously 
discussed, this difference would most likely lead to the compari-
son group being healthier at baseline (as borne out by our finding 
that those on clozapine had worse psychopathology as baseline) 
and less likely to be readmitted. Consequently, any such bias 
would have mostly likely produced an underestimate of the pro-
tective effect of clozapine so the protective effect of clozapine 
might be expected to be at least as strong as reported here. Indeed, 
some variables that we adjusted for may have been suboptimally 
measured due to limitations in data collection. For example, 
patients likely to have been non-compliant with their medication, 
were defined as those who had ever been treated by a depot or 
subject to a CTO. At 12% of our cohort, this is likely to be an 
underestimate of the prevalence of non-compliance, as it is dif-
ficult to identify patients who do not take their prescribed regular 
medication, and thus include such patients in our analyses. 
Clozapine is well recognised for its effectiveness in treating treat-
ment-resistant schizophrenia (Wimberley et al., 2017). It is likely 
the mechanism for clozapine reducing the risk of readmission is 
that it improves certain domains of mental health which are nor-
mally problematic for patients with schizophrenia and schizoaf-
fective disorder, and warrant readmission. However, this 
investigation did not compare the severity of these domains 
before and after initiation on clozapine. This was because HoNOS 
scores are not always recorded frequently enough in clinical 
practice to measure these changes over small time periods. 
Indeed, the exact causal mechanism that leads to the benefits of 
clozapine remain unclear. It is important that subsequent studies 
further elucidates this, and the influence concomitant treatments 
such as psychotherapy may have on clinical outcomes, as patients 
may undergo both pharmacological and psychological therapies. 
Future research should take the aforementioned limitations into 
account, by investigating the effects of long-term prescribing of 
clozapine, including patients on polypharmacy, and adjusting for 
potential confounding variables not considered by this investiga-
tion. Lastly, power appears to have been an issue in this study, as 
shown by the sensitivity analysis excluding all patients from the 
geographic catchment, including those who were homeless. This 
is likely to be a power issue as this sensitivity analysis excluded 
171 patients, with only a slight change in the HR but a large 
change in the p-value.
Figure 2. Kaplan–Meier Curves comparing those who were newly 
prescribed clozapine with those who were not: displaying the 
proportion of patients with schizophrenia and schizoaffective disorder 
who were not readmitted into inpatient mental health services over the 
follow-up period (n=3651).
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The results of this study have important clinical implications, 
which may be relevant for future clinical practice. Clozapine 
appears to reduce readmission rates into secondary mental health 
services. This highlights a potential benefit of prescribing clozap-
ine for use in treatment-resistant schizophrenia and schizoaffec-
tive disorder, which is currently underused in clinical practice, 
despite treatment guidelines (Howes et al., 2012). However, 
more research addressing the above limitations is required, 
before such benefit may be translated into clinical practice.
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